IBDEI2M8 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1325,0)
 ;;=OUTPT NEW PATIENT^3^104
 ;;^UTILITY(U,$J,358.4,1326,0)
 ;;=OUTPT ESTABLISHED PATIENT^2^104
 ;;^UTILITY(U,$J,358.4,1327,0)
 ;;=OUTPT CONSULTATIONS^4^104
 ;;^UTILITY(U,$J,358.4,1328,0)
 ;;=NURSING VISIT ONLY^1^104
 ;;^UTILITY(U,$J,358.4,1329,0)
 ;;=INITIAL OBSERVATION^9^104
 ;;^UTILITY(U,$J,358.4,1330,0)
 ;;=SAME DAY ADM/DISCHARGE^12^104
 ;;^UTILITY(U,$J,358.4,1331,0)
 ;;=INPT CONSULTATIONS^5^104
 ;;^UTILITY(U,$J,358.4,1332,0)
 ;;=INITIAL HOSPITAL CARE^6^104
 ;;^UTILITY(U,$J,358.4,1333,0)
 ;;=SUBSEQUENT HOSPITAL CARE^7^104
 ;;^UTILITY(U,$J,358.4,1334,0)
 ;;=HOSPITAL CARE D/C SERVICES^8^104
 ;;^UTILITY(U,$J,358.4,1335,0)
 ;;=SUBSEQUENT OBSERVATION CARE^10^104
 ;;^UTILITY(U,$J,358.4,1336,0)
 ;;=OBSERVATION CARE D/C SERVICES^11^104
 ;;^UTILITY(U,$J,358.4,1337,0)
 ;;=PROLONGED SERVICES^5^105
 ;;^UTILITY(U,$J,358.4,1338,0)
 ;;=VENOUS^6^105
 ;;^UTILITY(U,$J,358.4,1339,0)
 ;;=BP MONITORING^1^105
 ;;^UTILITY(U,$J,358.4,1340,0)
 ;;=MEDICATION^4^105
 ;;^UTILITY(U,$J,358.4,1341,0)
 ;;=CARDIOVASCULAR^2^105
 ;;^UTILITY(U,$J,358.4,1342,0)
 ;;=CATHETER^3^105
 ;;^UTILITY(U,$J,358.4,1343,0)
 ;;=HEMODIALYSIS-ESRD^14^106
 ;;^UTILITY(U,$J,358.4,1344,0)
 ;;=PERITONEAL DIALYSIS ENCOUNTER^23^106
 ;;^UTILITY(U,$J,358.4,1345,0)
 ;;=CARDIOLOGY/CARDIORENAL SYNDROME^2^106
 ;;^UTILITY(U,$J,358.4,1346,0)
 ;;=COMPLICATIONS/OTHER^4^106
 ;;^UTILITY(U,$J,358.4,1347,0)
 ;;=CYSTIC KIDNEY DISEASE^5^106
 ;;^UTILITY(U,$J,358.4,1348,0)
 ;;=DIABETES/DIABETIC RENAL DISEASE^6^106
 ;;^UTILITY(U,$J,358.4,1349,0)
 ;;=FLUID/ELECTROLYTE DISORDER^8^106
 ;;^UTILITY(U,$J,358.4,1350,0)
 ;;=GENERAL SYMPTOMS^9^106
 ;;^UTILITY(U,$J,358.4,1351,0)
 ;;=GENITAL/URINARY^10^106
 ;;^UTILITY(U,$J,358.4,1352,0)
 ;;=HEMATOLOGY^12^106
 ;;^UTILITY(U,$J,358.4,1353,0)
 ;;=HYPERTENSION^15^106
 ;;^UTILITY(U,$J,358.4,1354,0)
 ;;=INFECTIOUS DISEASE^16^106
 ;;^UTILITY(U,$J,358.4,1355,0)
 ;;=NEPHRITIS GLUMERULONEPHRITIS^18^106
 ;;^UTILITY(U,$J,358.4,1356,0)
 ;;=NEPHRITIS INTERSTITIAL^19^106
 ;;^UTILITY(U,$J,358.4,1357,0)
 ;;=NEPHROTIC SYNDROME^21^106
 ;;^UTILITY(U,$J,358.4,1358,0)
 ;;=OBSTRUCTIVE UROPATHY^22^106
 ;;^UTILITY(U,$J,358.4,1359,0)
 ;;=TRANSPLANT^25^106
 ;;^UTILITY(U,$J,358.4,1360,0)
 ;;=CKD/KIDNEY DISEASE^3^106
 ;;^UTILITY(U,$J,358.4,1361,0)
 ;;=HEMODIALYSIS-AKI^13^106
 ;;^UTILITY(U,$J,358.4,1362,0)
 ;;=ACUTE KIDNEY INJURY^1^106
 ;;^UTILITY(U,$J,358.4,1363,0)
 ;;=GLOMERULAR DISEASE^11^106
 ;;^UTILITY(U,$J,358.4,1364,0)
 ;;=KIDNEY INVOLVMNT IN SYSTEMIC DISEASE^17^106
 ;;^UTILITY(U,$J,358.4,1365,0)
 ;;=NEPHROLITHASIS^20^106
 ;;^UTILITY(U,$J,358.4,1366,0)
 ;;=POISONING & INTOXICATIONS^24^106
 ;;^UTILITY(U,$J,358.4,1367,0)
 ;;=DIALYSIS^7^106
 ;;^UTILITY(U,$J,358.4,1368,0)
 ;;=ESTABLISHED PATIENT^1^107
 ;;^UTILITY(U,$J,358.4,1369,0)
 ;;=CONSULTATIONS/OPINIONS^2^107
 ;;^UTILITY(U,$J,358.4,1370,0)
 ;;=NEW PATIENTS^3^107
 ;;^UTILITY(U,$J,358.4,1371,0)
 ;;=NEUROLOGY/SEIZURE^7^108
 ;;^UTILITY(U,$J,358.4,1372,0)
 ;;=EEG^4^108
 ;;^UTILITY(U,$J,358.4,1373,0)
 ;;=SLEEP TESTING^9^108
 ;;^UTILITY(U,$J,358.4,1374,0)
 ;;=MUSCLE TESTING/EMG^6^108
 ;;^UTILITY(U,$J,358.4,1375,0)
 ;;=EVOKED POTENTIAL^5^108
 ;;^UTILITY(U,$J,358.4,1376,0)
 ;;=BIOPSY^2^108
 ;;^UTILITY(U,$J,358.4,1377,0)
 ;;=AUTONOMIC FUNCTION TESTS^1^108
 ;;^UTILITY(U,$J,358.4,1378,0)
 ;;=STEREOTACTIC^10^108
 ;;^UTILITY(U,$J,358.4,1379,0)
 ;;=EDUCATION^3^108
 ;;^UTILITY(U,$J,358.4,1380,0)
 ;;=NEUROSTIMULATORS^8^108
 ;;^UTILITY(U,$J,358.4,1381,0)
 ;;=SEIZURES/EPILEPSY/SPELLS^14^109
 ;;^UTILITY(U,$J,358.4,1382,0)
 ;;=CEREBROVASCULAR DISEASE^2^109
 ;;^UTILITY(U,$J,358.4,1383,0)
 ;;=DIZZINESS^3^109
